Home > Neurology > IHC 2021 > Pharmacological Treatment > Galcanezumab effective in patients with episodic or chronic cluster headache

Galcanezumab effective in patients with episodic or chronic cluster headache

Presented By
Dr Charly Gaul, Headache Clinic Königstein, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
IHC 2021
Trial
Phase 3
In an open-label safety study, which implemented a dosing strategy to more closely approximate clinical practice, treatment with galcanezumab improved patient-reported cluster headache in most patients with episodic or chronic cluster headache [1]. Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and prevents its biological activity without blocking the CGRP receptor. The phase 3b, open-label safety CGAR study (NCT02797951) evaluated the safety of galcanezumab within the context of expected medical practice in patients (n=163) with episodic or chronic cluster headache. Dr Charly Gaul (Headache Clinic Königstein, Germany) presented a post hoc efficacy analysis from this study. Using the Patient Global Impression of Improvement (PGI-I), 81% of patients reported improvement of their cluster headache condition as very much better, much b...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on